Gut Microbiota, Microbial Metabolites, and Growth Trajectories in Fetal Growth Restriction and Small for Gestational Age Infants: A Structured Narrative Review of the First 1000 Days

Background/Objectives: Fetal growth restriction (FGR) and small for gestational age (SGA) status are related but distinct entities, both linked to increased long-term cardiometabolic risk, potentially mediated by the gut microbiome–metabolome axis during the first 1000 days of life. This review synthesizes current evidence on gut dysbiosis, host and microbial metabolites, catch-up growth, and probiotic interventions in these populations. Methods: A structured narrative review of human and animal studies published in English between January 2010 and August 2026 was conducted across PubMed/MEDLINE, Embase, Scopus, and Web of Science. Results: Reported alterations in gut microbial composition and function are heterogeneous, without a single, consistently replicated taxonomic signature, and much of the evidence derives from SGA or preterm cohorts rather than antenatally confirmed FGR. Metabolomic studies recurrently implicate host amino-acid, acylcarnitine, and phospholipid pathways, but small samples, heterogeneous platforms, and incomplete reporting of metabolite identification, normalization, and gestational age at sampling limit comparability. Mechanistic animal studies support selected pathways linking maternal dysbiosis to placental dysfunction, though the full sequence from early microbial alterations to catch-up growth and cardiometabolic risk remains unproven in humans. Gut microbial diversity has been associated with catch-up weight gain in one small SGA cohort, and delayed microbiota maturation with postnatal growth failure in some, but not all, preterm cohorts. Evidence from preterm populations supports benefits of selected probiotic preparations for some neonatal outcomes, while effects on short-term growth are modest and heterogeneous; probiotics have not been shown to modify catch-up-growth quality or long-term cardiometabolic outcomes after FGR, and safety and efficacy appear product-, strain-, and population-specific. Conclusions: Current evidence supports plausible, partially demonstrated mechanistic links between FGR/SGA, gut dysbiosis, and cardiometabolic programming, but not a fully validated causal pathway in humans. Future studies should distinguish FGR from SGA, assess body composition alongside growth, and evaluate product-specific probiotic efficacy and safety with long-term follow-up.